Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children (Lef for IPH)
Idiopathic Pulmonary Hemosiderosis, Leflunomide
About this trial
This is an interventional treatment trial for Idiopathic Pulmonary Hemosiderosis focused on measuring Idiopathic pulmonary hemosiderosis, Leflunomide, glucocorticoid
Eligibility Criteria
Inclusion Criteria: Age range from 6 months to 18 years old; Diagnose as IPH; Parents or guardians agree to treatment and sign a written informed consent form. Exclusion Criteria: Individuals who are allergic to any ingredients used in leflunomide tablets; Complicated with serious basic diseases (such as systemic malignant diseases, heart failure, liver and kidney failure, immune deficiency, serious infectious diseases, Lung transplantation or other patients with immediate surgical indications); Patients with other lung diseases; Have a history of abnormal coagulation or abnormal coagulation function in the past; Clinical trial participants who have previously participated in the treatment of flumiphene; Other situations where the researcher deems it inappropriate to participate in the study.
Sites / Locations
- Sun Yat-sen Memorial Hospital of Sun Yat-sen UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
IPH Patients
Control Group
Leflunomide+Steroid treatment
Steroid treatment